FMR1 and fragile X syndrome: While there are many drug interventions that reduce behavioral deficits in Fmr1 mice and efforts to translate these preclinical breakthroughs into clinical trials for Fragile X Syndrome (FXS) (Tranfaglia, 2011; Wijetunge et al., 2013; Budimirovic et al., 2017; Berry-Kravis et al., 2018; Erickson et al., 2018), evidence-based clinical interventions are almost non-existent (Berry-Kravis et al., 2018).